Literature DB >> 3519939

Pharmacological properties of acetorphan, a parenterally active "enkephalinase" inhibitor.

J M Lecomte, J Costentin, A Vlaiculescu, P Chaillet, H Marcais-Collado, C Llorens-Cortes, M Leboyer, J C Schwartz.   

Abstract

Acetorphan, i.e. N-[(R,S)-3-acetylmercapto-2-benzylpropanoyl]-glycine, benzyl ester, is a lipophilic derivative of Thiorphan, a potent inhibitor of "enkephalinase" (EC 3.4.24.11). On purified enkephalinase its inhibitory potency was approximately 1000 fold less than that of Thiorphan but became close to the latter (nanomolar) when it was incubated previously with cerebral membranes. After parenteral administration to mice and rats (1-10 mg/kg) extensive inhibition of cerebral enkephalinase was shown by the depressed enzyme activity in brain membranes from treated animals and the long-lasting potentiation of analgesia elicited by (D-Ala2,Met5)enkephalin (i.c.v.). This suggests that acetorphan easily enters the brain where the active Thiorphan is released. Parenteral acetorphan elicited a series of naloxone-reversible, opioid-like effects, most of which were described previously with intracerebral Thiorphan or other enkephalinase inhibitors. Antinociceptive effects were found in some tests (hot plate jump and phenylbenzoquinone-induced writhing) but not in others (hot plate licking and tail withdrawal). "Antidepressant" effect was found in the "mouse despair" test and antidiarrhoeal effect in the rat castor oil test. Acetorphan also elicited significant increases and decreases in turnover indexes of serotonin and noradrenaline, respectively, in mouse cerebral cortex. In mice chronically treated with acetorphan, the antinociceptive activity of the compound was not modified markedly and no overt withdrawal symptom could be observed after either treatment interruption or administration of naloxone.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3519939

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  26 in total

Review 1.  Effective Delivery of Male Contraceptives Behind the Blood-Testis Barrier (BTB) - Lesson from Adjudin.

Authors:  Haiqi Chen; Dolores D Mruk; Weiliang Xia; Michele Bonanomi; Bruno Silvestrini; Chuen-Yan Cheng
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

2.  Antinociceptive effects of ONO-9902, an enkephalinase inhibitor, after visceral stress condition in rats.

Authors:  Y Yamamori; Y Saito; M Kaneko; Y Kirihara; S Sakura; Y Kosaka
Journal:  Can J Anaesth       Date:  1996-11       Impact factor: 5.063

Review 3.  Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers.

Authors:  Marlyn Laksitorini; Vivitri D Prasasty; Paul K Kiptoo; Teruna J Siahaan
Journal:  Ther Deliv       Date:  2014-10

Review 4.  Racecadotril.

Authors:  A J Matheson; S Noble
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

5.  Effects of aerosolised substance P on lung resistance in guinea-pigs: a comparison between inhibition of neutral endopeptidase and angiotensin-converting enzyme.

Authors:  J O Lötvall; B E Skoogh; P J Barnes; K F Chung
Journal:  Br J Pharmacol       Date:  1990-05       Impact factor: 8.739

Review 6.  Racecadotril versus loperamide: antidiarrheal research revisited.

Authors:  S Huighebaert; F Awouters; G N J Tytgat
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

7.  Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes.

Authors:  Luca Gallelli; Manuela Colosimo; Grazia A Tolotta; Daniella Falcone; Laura Luberto; Lucia S Curto; Pierandrea Rende; Francesca Mazzei; Norma M Marigliano; Giovambattista De Sarro; Salvatore Cucchiara
Journal:  Eur J Clin Pharmacol       Date:  2009-11-10       Impact factor: 2.953

8.  Steady-state level and turnover rate of the tripeptide Tyr-Gly-Gly as indexes of striatal enkephalin release in vivo and their reduction during pentobarbital anesthesia.

Authors:  C Llorens-Cortes; C Gros; J C Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

9.  Amelioration of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphan.

Authors:  S J Livingston; R D Sewell; K F Rooney; H J Smith
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

10.  Endopeptidase 24.15 inhibition and opioid antinociception.

Authors:  B Kest; M Orlowski; R J Bodnar
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.